PubMed Health⌕ Search

Biomedical subjects

C Shih

Publications and source records attributed to C Shih.

At least 55 records · Page 3Linked to original sources
PubMed1998

A sensitive and specific radioimmunoassay for LY309887, a potent inhibitor of glycinamide ribonucleotide formyltransferase.

LY309887, a reduced analogue of folic acid, is a potent inhibitor of glycinamide ribonucleotide formyltransferase and possesses a broad spectrum of antitumor activity. During preclinical studies using supplementation with oral folic acid, this second-generation inhibitor displayed both the desired safety profile and the pharmacology to warrant clinical investigation. A sensitive analytical method was needed to assess the pharmacokinetics of LY309887 due to the low doses planned for Phase I studies and the potential for low concentrations in plasma long after i.v. administration. We therefore undertook the development of a competitive RIA. A highly specific antiserum was raised in rabbits following immunization with LY309887 coupled to BSA. A RIA tracer was prepared by radioiodination of compound 389753, the adduct of LY309887 with p-tyramine. We developed a competitive-binding RIA procedure and used superparamagnetic particles coated with goat antirabbit IgG as a method for separating the bound and free forms of LY309887. The RIA is sensitive (0.5 ng/ml in serum and 25 ng/ml in urine), specific (negligible interference from endogenous folates), and reproducible (interassay coefficients of variation ranging from 8.1 to 15.4% and 7.6 to 8.3% for serum and urine controls, respectively). We used the RIA to assess the i.v. pharmacokinetics of LY309887 in both patients with metastatic cancer and dogs. The sensitivity of the RIA permitted the demonstration that serum concentrations of LY309887 decline in a multiexponential manner with a prolonged terminal elimination phase. We conclude that the RIA is a valid method for quantifying LY309887 in biological fluids.

Animals↗
PubMed1998

Triangular fibrocartilage perforations with bilateral negative ulnar variant wrists: a case report.

Triangular fibrocartilage (TFC) constitutes the major part in the triangular fibrocartilage complex, which stabilizes the distal radioulnar joint and functions as a cushion for axial compression forces. Tears in the TFC are often encountered with positive ulnar variance and regarded as part of a degenerative process of the ulnocarpal joint. They are occasionally seen as the result of trauma and are less likely to be found in a young population, especially in those who are in the first two decades of life, without causative traumatic injury. We report the case of a 12-year-old boy with bilateral negative ulnar variances with incidental findings of TFC tears in both wrists. This is a rare case, as he had no history of a traumatic event.

Cartilage, Articular↗
PubMed1997

Mercury-induced conformational changes and identification of conserved surface loops in plasma membrane aquaporins from higher plants. Topology of PMIP31 from Beta vulgaris L.

Aquaporins are integral membrane proteins occurring in mammals, plants, and microorganisms, which serve as channels that permit the bidirectional passage of water through cellular membranes. Higher plants contain abundant levels of aquaporins in both the tonoplast and plasma membrane. Aquaporins contain six transmembrane segments with three surface loops located at the apoplastic face of the membrane and two loops at the cytosolic side. In this study, we probed the topology of plasma membrane aquaporins to determine the effects of divalent cations on aquaporin conformation, and to identify structural features that distinguish plasma membrane intrinsic proteins from tonoplast intrinsic proteins. Plasma membrane vesicles from storage tissue of Beta vulgaris L. were subjected to limited proteolysis, and proteolytic fragmentation patterns were detected using affinity-purified antibodies recognizing aquaporins of 31-kDa. In its native membrane-associated state, the 31-aquaporin band, PMIP31, was refractory to proteolysis by trypsin. However, mercuric compounds specifically induced a conformational change resulting in the exposure of a proteolytic cleavage site and formation of a unique 22-kDa proteolytic fragment (p22). N-terminal sequence analysis of p22 established its identity as an aquaporin-derived fragment. Topological studies using sealed right-side-out plasma membrane vesicles established that the proteolytic cleavage site is located at surface loop C, the second apoplastic loop, immediately preceding the sequence Gly-Gly-Gly-Ala-Asn. The Gly-Gly-Gly-Ala-Asn-X-X-X-X-Gly-Tyr motif of loop C and a 14 amino acid motif in apoplastic loop E, Thr-Gly-Ile/Thr-Asn-Pro-Ala-Arg-Ser-Leu/Phe-Gly-Ala-Ala-Ile/Val-Ile/ Val-Phe/Tyr-Asn are completely conserved in all known higher plant aquaporins of plasma membrane origin and are not present in any of the known tonoplast intrinsic proteins. These results demonstrate that the two highly conserved plasma membrane intrinsic protein surface loops are structural features that clearly distinguish plasma membrane from tonoplast aquaporins.

Amino Acid Sequence↗
PubMed1997

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl ]-benzoyl]-L-glutamic acid (LY231514) is a novel pyrrolo[2,3-d]pyrimidine-based antifolate currently undergoing extensive Phase II clinical trials. Previous studies have established that LY231514 and its synthetic gamma-polyglutamates (glu3 and glu5) exert potent inhibition against thymidylate synthase (TS). We now report that LY231514 and its polyglutamates also markedly inhibit other key folate-requiring enzymes, including dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). For example, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibition against TS, DHFR, and GARFT, respectively. In contrast, although a similar high level of inhibitory potency was observed for the parent monoglutamate against DHFR (7.0 nM), the inhibition constants (Ki) for the parent monoglutamate are significantly weaker for TS (109 nM) and GARFT (9,300 nM). The effects of LY231514 and its polyglutamates on aminoimidazole carboxamide ribonucleotide formyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase were also evaluated. The end product reversal studies conducted in human cell lines further support the concept that multiple enzyme-inhibitory mechanisms are involved in cytotoxicity. The reversal pattern of LY231514 suggests that although TS may be a major site of action for LY231514 at concentrations near the IC50, higher concentrations can lead to inhibition of DHFR and/or other enzymes along the purine de novo pathway. Studies with mutant cell lines demonstrated that LY231514 requires polyglutamation and transport via the reduced folate carrier for cytotoxic potency. Therefore, our data suggest that LY231514 is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multiple inhibition of several key folate-requiring enzymes via its polyglutamated metabolites.

5,10-Methylenetetrahydrofolate Reductase (FADH2)↗
PubMed1997

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.

PURPOSE: Cell cycle-related events in CCRF-CEM lymphocytic leukemia cells were examined subsequent to inhibition of thymidylate synthase (TS) or GAR formyltransferase (GARFT) and prior to cell death or stasis. METHODS: Cell populations were treated with the GARFT inhibitors 6R-5, 10-dideazatetrahydrofolate (Lometrexol) or LY309887, the TS inhibitor ZD1694, or the multitargeted antifolate LY231514. DNA content, nucleoside precursor incorporation and proliferating cell nuclear antigen (PCNA) expression as functions of drug treatment were assessed by multiparameter flow cytometry. Cellular respiration was measured by MTT analysis and apoptosis was detected by extraction of DNA fragments. RESULTS: Cell populations treated for up to 96h with lometrexol or LY309887 did not replicate and maintained a cell cycle distribution with distinct G1, S and G2/M regions. The number of S phase cells in treated populations was slightly elevated relative to control as measured by DNA content and PCNA. However, these cells were unable to incorporate 5-bromodeoxyuridine (BrdU). Throughout treatment, cells incubated with GARFT inhibitors maintained intact membranes and respired at a level comparable to untreated cells. In contrast, ZD1694 as well as LY231514, induced synchronization of the treatment population at the G1/S interface within 12h of drug addition. This was followed by synchronous entry of the population into S phase. After 24 h of treatment, more than 90% of the cells were capable of incorporating BrdU and stained positive for PCNA. DNA fragmentation occurred in cells treated with ZD1694 or LY231514 but not in those treated with GARFT inhibitors. In addition, the viable cells remaining after 24-48 h of treatment with ZD1694 or LY231514 were respiring at twice the level of untreated cells. CONCLUSION: These results demonstrate that the distinct endpoints of GARFT and TS inhibition are preceded by distinct cell cycle and metabolic alterations.

Acyltransferases↗
PubMed1997

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

The above data indicate that LY335979 displays the following characteristics of an 'ideal modulator' of Pgp-mediated multidrug resistance: high affinity binding to Pgp, high potency for in vitro reversal of drug resistance, high therapeutic index (activity was demonstrated at doses ranging from 1-30 mg/kg) observed in in vivo antitumor efficacy experiments, and a lack of pharmacokinetic interactions that alter the plasma concentration of coadministered oncolytic agents. These desirable features strongly suggest that LY335979 is an exciting new clinical agent to test the hypothesis that inhibition of P-glycoprotein activity will result in reversal of multidrug resistance in human tumors.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMed1997

Neurogenic substance P stimulates osteogenesis in vitro.

Previous studies have shown that there is colocalization of substance P (SP) and calcitonin gene-related peptide (CGRP) immunoreactive nerve fibers in bone, periosteum and bone marrow. Because SP may also possibly play a role in bone formation, we decided to test whether it has an osteogenic stimulating effect on developing bone in vitro. To this end, 0.4, 4 and 40 micrograms/ml of SP in BGJb medium was added daily to 3 million light density (LD) bone marrow white cells which were separated by Ficoll-Paque density gradient separation then seeded onto a previously prepared fibroblast feeder layer in Petri dishes. Seven days after adding SP, in the control without SP there were 2 bone colonies; with 0.4 micrograms of SP there were 3 colonies; with 4 micrograms there were 5 colonies; with 40 micrograms there were 7 colonies. In addition, there was an increase in the size of bone colonies in the SP-added group. The results indicated that SP had a dose-related osteogenic stimulating effect. The increase in the number and size of bone colonies by SP was probably caused by stimulating stem cell mitosis, osteoprogenitor cell differentiation or osteoblastic activity.

Animals↗
PubMed1997

Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen.

We examined the full-length hepatitis B virus (HBV) envelope (surface antigen or HBV small surface antigen [HBsAg]) sequences of 12 different liver samples from 10 different hepatoma-containing chronic carriers. Surprisingly, novel and frequent mutations occurred predominantly at amino acids 40 and 47 of HBsAg, in addition to within a known protective B-cell epitope (so-called group a determinant of HBsAg 124-148). Approximately 58% of chronic carriers contain mutations at the group a determinant. The mutation frequency at the hotspot codons 40 and 47 is approximately 83%, 1 order of magnitude higher than at the known polymorphic sites of subtype-specific determinants at codons 122 and 160, which is approximately 4%. This new mutational domain is found to coincide with a major histocompatibility complex class I-restricted T-cell epitope. The potential biological significance of this novel mutation in the immunopathogenesis of HBV chronic carriers is discussed.

Adult↗
PubMed1997

Evaluation of tibial cortical bone by ultrasound velocity in oriental females.

In order to evaluate the feasibility of detecting bone status by measuring cortical ultrasound velocity, ultrasonic transmission velocity of the anterior cortex of shin was measured on 175 normal Chinese females aged 31-75 years (mean 52.3 +/- SD 9.1 years). The data were compared with bone mineral density (BMD) of the lumbar spine and/or hip measured by dual energy X-ray absorptiometry (DXA), which was performed on the same day as speed of sound (SOS) examination. Comparison was made with SOS of Caucasian women previously reported in the literature. SOS of three volunteers measured by two different operators were also enrolled in our study for precision testing. The mean value of SOS of the 175 females was 3850.7 +/- 119.3 m s-1 (range: 3411.7-4220.5 m s-1), the peak value being in the fourth decade. The rate of decrease of transmission velocity per decade from fourth decade to fifth decade was 1.7%, while that of fifth decade to sixth decade was 2.2% and that of sixth decade to seventh decade was 4.0%. The interoperative and intraoperative coefficient variance with and without reposition were under 0.32%. SOS moderately correlated with BMD at different sites, the best correlation being with the lumbar spine anteroposterior projection (r = 0.509; p < 0.0001, Pearson's test). There were significant differences in SOS between pre- and post-menopausal groups (p = 0.01, ANOVA test), and between peri- and post-menopausal groups (p = 0.02), but there was no correlation of body weight and height with SOS. SOS also inversely correlated with age and post-menopausal duration. The mean value of SOS in our study was similar to that of Caucasians, but the rate of decrease over 50 years of age was faster. The rate of decline of tibial cortical SOS was similar to that of trabecular bone as previously reported in the literature. As there is a significant decrease of SOS in older females, and older Oriental females suffer from an accelerated cortical bone loss, it is concluded that cortical bone SOS may be a useful method for detecting potential osteoporotic patients in this ethnic group.

Absorptiometry, Photon↗
PubMed1997

Calcitonin gene related peptide enhances bone colony development in vitro.

Recent evidence suggests that sensory nerve fibers of the dental pulp secrete calcitonin gene related peptide alpha exactly where secondary or tertiary dentin is mineralized. In addition, calcitonin gene related peptide raises the level of cyclic adenosine monophosphate in osteoblasts, indicating a potential effect on secretory activity in bone. Because calcitonin and calcitonin gene related peptide are formed from the same gene, the authors tested whether calcitonin gene related peptide or calcitonin has an osteogenic potential in vitro. To this end, 0.01, 0.1, and 1 microg/ml of salmon calcitonin or rat calcitonin gene related peptide in Bigger, Gwatkin, Jackson b medium was added daily to 3 x 10(6) rat light density bone marrow leukocytes that were separated with the Ficoll-Paque density gradient separation method, then seeded on a previously prepared fibroblast layer in Petri dishes. After 7 days, the number and size of bone colonies formed in the calcitonin gene related peptide (0.1 or 1 microg/ml) added group was significantly greater than that of the control group. There was no statistically significant difference between the calcitonin added and control groups. Calcitonin gene related peptide has an osteogenic stimulating effect, either by stimulating stem cell mitosis or osteoprogenitor cell differentiation (or both), whereas salmon calcitonin has no effect.

Animals↗
PubMed1997

Metabolism and disposition of the antifolate LY231514 in mice and dogs.

The metabolism and disposition of LY231514 was studied in mice and dogs. LY231514 is a novel pyrrotopyrimidine-based multi-target antifolate (MTA) showing broad in vivo antitumor activity in mouse models and is currently in phase II human clinical trials. Doses (iv) of the compound showed high plasma levels, resulting in AUC values of 30-33 micrograms-hr/ml for mice and dogs after 20 and 7.5 mg/kg doses, respectively. The compound was eliminated rapidly. Half-life values for mice and dogs were about 7 and 2 hr, respectively. In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans. Fecal elimination was the major excretion pathway in mice after single iv doses of [14C]LY231514. Urine constituted the major route of excretion in dogs. Parent LY231514 accounted for the majority of urinary radiocarbon in mice (90%) and dogs (68%). Minor metabolites were found in urine, but the amounts were too small to isolate or identify. Based on an earlier observation that LY231514 photodegraded to produce reaction products having similar retention times as these minor urinary isolates, a photo-oxidation system was developed which in fact produced these metabolites. Subsequently, these photolytically-produced materials were used as standards to identify two novel in vivo metabolites formed by oxidation of the pyrrolo-pyrimidine ring system of LY231514. The oxidative transformations are similar to those observed for tryptophan and other indoles in that the pyrrole ring is oxidized to give an amide; further oxidation cleaves this ring, one ring carbon is lost, and a ketone is formed.

Animals↗
PubMed1997

Measuring tibial cortical bone status by ultrasonic velocity.

BACKGROUND: Post-menopausal osteoporosis has become a serious public health problem with the increase of the geriatric population. Dual energy x-ray absorptiometry (DEXA) is the most common method for diagnosis of osteoporosis by quantitative change of bone, but recently there is increasing interest in measuring both qualitative and quantitative changes of bone by ultrasound. This study measured ultrasound velocity of anterior tibial cortex to evaluate the feasibility of detecting cortical bone status by speed of sound (SOS). METHODS: SOS in anterior tibial cortex was measured on 205 females referred from clinicians for routine bone mineral density (BMD) measurement. These females were divided into 2 groups. Group 1 consisted of 170 females aged from 30 to 75 years (mean: 55.2 +/- 9.3 years), who never received estrogen therapy. Group 2 consisted of 35 females in the post-menopausal status aged ranged from 45 to 69 years (mean: 51.5 +/- 3.5 years), who had received estrogen gel or oral estrogen tablet (0.625 mg/day) replacement therapy for prevention of postmenopausal osteoporosis for a period of 6 to 68 months (mean: 25.3 +/- 2.3 months). For precision test, 3 volunteers whose SOS was measured by 2 different operators were also enrolled in our study. BMD by DEXA of L-spine and/or hip was also performed on the same day of SOS examination. We analyzed the precision of this new method, calculated mean value of SOS to see if there was any difference with respect to pre- at, and post-menopausal status between estrogen users and nonusers by SOS, and tried to find the relationship of SOS with body habitus and BMD. RESULTS: Mean value of SOS of group 1 females was 3852 +/- 150.3 m/s, with peak value in the fourth decade. There were inverse correlation of SOS with age (r = -0.36, p < 0.0005) and the period after menopause (r = -0.32, p < 0.0005). The decreasing rate of SOS per decade from 31 to 50 years of age was 1.7%, while that of 51 to 70 years was 4.3% in group 1 females. With regard to menopausal status, there was significant difference of SOS between pre- and post-menopausal females (p = 0.01, ANOVA test), between at and post-menopausal females (p = 0.02). Significant difference (p < 0.05, ANOVA test) between group 2 estrogen users and group 1 postmenopausal nonusers was also noted. There was no evidence of correlation of body weight or height with SOS. Both inter- and intra-operator precision of SOS was under or equal to 0.32%. Moderately correlation between SOS and BMD was noted. CONCLUSIONS: Our study demonstrated good precision in SOS measurement of tibial cortical status. It was inversely correlated with age and post-menopausal period; it also significantly discriminated estrogen users from nonusers, and pre-, at from post-menopausal subgroups. However, for further evaluation of the relationship between SOS and the most severe complication of osteoporosis, i.e. osteoporotic fracture, population-based long-term followup is still required.

Adult↗
PubMed1996

Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts.

The importance of polyglutamation for the activation of natural folates and classical antifolates and recent evidence for the role of dietary folate as a biochemical modulator of antifolate efficacy led us to investigate the influence of changes in dietary folate on folylpolyglutamate synthetase (FPGS) activity. Activities were measured using lometrexol (6R-5,10-dideazatetrahydrofolic acid) as a substrate for FPGS with extracts of murine tissues, murine tumors, and human tumor xenografts from mice on standard diet or low folate diet. Tissues and tumors from mice on standard diet exhibited a 6-fold range of FPGS activity. Kidney had the lowest activity (36 pmol/hr.mg protein), followed by the human xenograft PANC-1 pancreatic carcinoma (46 pmol/hr.mg protein), liver (109 pmol/hr.mg protein), murine C3H mammary tumor (112 pmol/hr.mg protein), and the human xenograft MX-1 mammary carcinoma (224 pmol/hr.mg protein). In response to restricted dietary folate, four out of five tissues had significantly increased (25-50%) FPGS activity. Only the tumor with highest FPGS activity under standard diet conditions (MX-1 mammary) did not respond to low folate diet. The results indicate that changes in dietary folate intake can modulate FPGS activity significantly in vivo and suggest that the tissue distribution and toxicities of classical antifolates requiring polyglutamation for activation and cellular retention will be influenced significantly by folate status of the host.

Animals↗
PubMed1996

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.

Recent clinical trials with lometrexol [(6R)-5,10-dideazatetrahydrofolate] have revealed a level of toxicity in humans that was not predicted on the basis of previous in vivo preclinical studies. Because standard laboratory animal diets contain high levels of folic acid relative to human folate intake, the toxicity and therapeutic activity of lometrexol was studied in mice under conditions of restricted dietary folate intake. Remarkably, the lethality of this drug increased by three orders of magnitude in mildly folate-deficient mice, mimicking the unexpected toxicity seen in humans. Lometrexol had limited therapeutic activity in folate-deficient mice bearing the C3H mammary adenocarcinoma, compared with the substantial therapeutic index for treatment of this tumor in animals on standard diet. When folic acid was administered p.o. to mice that were mildly folate deficient, antitumor activity was again observed at nontoxic doses of lometrexol, and the range of lometrexol doses that allowed safe therapeutic use of this drug increased at higher dietary folate intake. At a fixed dose of lometrexol, the antitumor effects in animals were dependent on the level of dietary folate and went through a distinct optimum. Excessively high folate intake reversed the antitumor effects of lometrexol. Optimization of the folic acid content in the diet and of the lometrexol dosage are predicted to have substantial impact on the clinical activity of this class of drugs.

Adenocarcinoma↗
PubMed1996

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.

Wortmannin, a fungal metabolite, was identified as a potent inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI 3-kinase). Due to the importance of PI 3-kinase in several intracellular signaling pathways, structure-activities studies on wortmannin analogs were performed in an effort to understand the structural requirements necessary for PI 3-kinase inhibition. Since wortmannin is an irreversible inhibitor of PI 3-kinase, it was postulated that covalent attachment at the electrophilic C-21 site was a possible mode of action for PI 3-kinase inhibition. We have prepared various wortmannin analogs which address the possibility of this mechanism. Of particular interest are compounds which affect the C-21 position of wortaminnin either sterically or electronically. Our results support the conclusion that nucleophilic addition by the kinase onto the C-21 position of wortmannin is required for inhibition of PI 3-kinase by wortmannin analogs. Additionally, we have prepared several D-ring analogs of wortmannin, and their activities are reported herein. We conclude that the wortmannin D ring is an important recognition site since modifications have such a dramatic effect on inhibitor potency. Finally, the identification of 17beta-hydroxywortmannin represents the first reported subnanomolar inhibitor of PI 3-kinase. These studies, along with in vivo antitumor experiments, suggest that the mechanism of PI 3-kinase inhibition correlates to the associated toxicity observed with wortmannin-based inhibitors of PI 3-kinase.

Androstadienes↗
PubMed1996

Peripheral blood mononuclear cells develop into multinucleated osteoclasts in tissue culture.

BACKGROUND: Previous studies have shown that osteoclasts are derived from mononuclear cells of hemopoietic bone marrow and peripheral blood. The purpose of this study was to demonstrate the presence of multinucleated osteoclasts after adding mononuclear cells from peripheral blood into established explants of fetal mouse calvaria in vitro. METHODS: In order to utilize osteoclast-free bone, the fetal calvariae were obtained from 13-14-day pregnant Swiss Webster mice and cultured in BGJb medium for 9 days. At day 9, peripheral blood mononuclear cells were isolated as a light density layer from adult Swiss Webster mice with the Ficoll-Paque density gradient separation method and co-cultured with the osteoclast-free, fetal mouse calvaria. RESULTS: After 10 days of co-culture, multinucleated cells, which have all the characteristics of osteoclasts, were found in juxtaposition to seams of woven bone. Two multinucleated osteoclasts per one million light density peripheral blood mononuclear cells were found in the experimental group; none were found in the mononuclear cell-free control group. CONCLUSIONS: Peripheral blood mononuclear cells can give rise to multinucleated osteoclasts in developing bone in vitro but will not develop without bone.

Animals↗
PubMed1996

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Lometrexol, a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically. Unexpected observations of delayed cumulative toxicity prompted a search for a second generation antimetabolite with a more favorable biochemical, pharmacological and toxicological profile. LY309887, 6R-2',5'-thienyl-5, 10-dideazatetrahydrofolic acid, had 9-fold greater potency to inhibit GARFT (Ki = 6.5 nM) compared to lometrexol. Like lometrexol, LY309887 was activated by folpolyglutamate synthetase, however, it had a lower first order rate constant. In vitro and in vivo data were consistent with these observations: polyglutamation of LY309887 was less extensive compared to lometrexol and livers of mice accumulated fewer polyglutamates of LY309887 than polyglutamates of lometrexol. The affinities of these two compounds for isoforms of human folate receptors (FR) were compared. Lometrexol had a 6-fold higher affinity for FR alpha than LY309887 and both compounds had higher affinity for the alpha isoform compared to the beta isoform. The selectivity of LY309887 for FR alpha (beta (Ki)/ alpha (Ki) = 10.5) was twice that of lometrexol's (beta / alpha = 5.0). Lometrexol and LY309887 were potent cytotoxic compounds against the human leukemia cell line CCRF-CEM with IC50's of 2.9 nM and 9.9 nM, respectively. In vivo, LY309887 was more potent than lometrexol at inhibiting tumor growth in the C3H mammary murine tumor model and several tumor xenografts. Excellent efficacy was achieved by both compounds in several colon xenografts. In two pancreatic human xenografts, LY309887 achieved greater efficacy than lometrexol. In summary, the biochemical and pharmacological properties of lometrexol and LY309887 support the hypothesis that these antifolates will have clinical activity against human solid tumors. LY309887 is a second generation GARFT inhibitor with biochemical and pharmacological properties which distinguish it from lometrexol and suggest that it will have broad antitumor activity, a different pharmacokinetic profile and produce less toxicity than lometrexol in cancer patients.

Acyltransferases↗